Publications by authors named "John Holcenberg"

Claim this Profile
A
Are we getting closer to using methotrexate in an optimal manner?
Barton A Kamen, Joseph R Bertino, John S Holcenberg, W Archie Bleyer

J Clin Oncol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).
Shana S Jacobs, Linda C Stork, Bruce C Bostrom, Ray Hutchinson, John Holcenberg

Pediatr Blood Cancer· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: a report from Children's Oncology Group Study CCG-1962.
Ioannis A Avramis, Eduard H Panosyan, Fred Dorey, John S Holcenberg, Vassilios I Avramis

Clin Cancer Res· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of oral aminopterin for adults and children with refractory acute leukemia.
Peter D Cole, Richard A Drachtman, Angela K Smith, Sarah Cate, Richard A Larson, John Holcenberg

Clin Cancer Res· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New insights on asparaginase.
John Holcenberg

J Pediatr Hematol Oncol· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
Blythe Thomson, Julie R Park, Judy Felgenhauer, Soheil Meshinchi, John Holcenberg

Pediatr Blood Cancer· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Douglas S Hawkins, Julie R Park, Blythe G Thomson, Judy L Felgenhauer, John S Holcenberg

Clin Cancer Res· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors.
Joel M Reid, Wenchun Qu, Stephanie L Safgren, Matthew M Ames, Mark D Krailo, John Holcenberg

J Clin Oncol· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal asparaginase therapy.
John Holcenberg

J Pediatr Hematol Oncol· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962).
Helen A Kurre, Alice G Ettinger, David L Veenstra, Paul S Gaynon, Janet Franklin, John S Holcenberg

J Pediatr Hematol Oncol· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.
Vassilios I Avramis, Susan Sencer, Antonia P Periclou, Harland Sather, Bruce C Bostrom, John S Holcenberg

Blood· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis